STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences: Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, Mass.Format: 1×1 meetingsParticipation Date: Tuesday, September 8, 2026Participant: Ahmed Mousa, Chief Executive Officer Cantor Global Healthcare Conference Location: Waldorf Astoria New York, New York, N.Y.Format: Fireside chat and 1×1 meetingsFireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ETWebcast: Link Participant: Ahmed Mousa, Chief Executive Officer For more information, please contact: Hans Jeppsson, CFO, +46 70 553 14 65, [email protected] About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
